Importance: Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth.

Subpopulation Considerations: Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate prenatal care may contribute to poor outcomes associated with preeclampsia in African American women.

Objective: To update the 1996 US Preventive Services Task Force (USPSTF) recommendation on screening for preeclampsia.

Evidence Review: The USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools, and the benefits and harms of treatment of screen-detected preeclampsia.

Findings: Given the evidence that treatment can reduce maternal and perinatal morbidity and mortality, and the well-established accuracy of blood pressure measurements, the USPSTF found adequate evidence that screening for preeclampsia results in a substantial benefit for the mother and infant. In addition, there is adequate evidence to bound the harms of screening for and treatment of preeclampsia as no greater than small. Therefore, the USPSTF concludes with moderate certainty that there is a substantial net benefit of screening for preeclampsia in pregnant women.

Conclusions And Recommendation: The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. (B recommendation).

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2017.3439DOI Listing

Publication Analysis

Top Keywords

screening preeclampsia
20
african american
16
preeclampsia
12
american women
12
screening
8
preventive services
8
services task
8
task force
8
associated preeclampsia
8
white women
8

Similar Publications

Objective: The aim of this study is to systematically examine the role of the pregnancy-associated plasma protein A (PAPP-A) serum biomarker in the first trimester screening of preeclampsia (PE).

Materials And Methods: A systematic search of the literature was conducted on PubMed via Medline, and Cochrane Library up to 8 November 2022, for prospective studies evaluating PAPP-A serum levels in first trimester pregnant women as a screening biomarker for PE. Eligible were all prospectively designed case-control or cohort studies, published in English.

View Article and Find Full Text PDF

Objectives: To investigate the clinical situation and pregnancy outcome of pregnant women with pulmonary arterial hypertension (PAH).

Methods: A retrospective analysis was conducted on 125 pregnant women with varying degrees of PAH who were treated in the Department of Obstetrics and Gynecology of the First Affiliated Hospital of the University of Science and Technology between January 2016 and January 2023. The patients were divided into the mild group (58 cases), the moderate group (42 cases), and the severe group (25 cases) based on the pulmonary artery systolic blood pressure (PASBP) measurements.

View Article and Find Full Text PDF

Objective: The aim of this study was to investigate the correlation between plateletcrit (PCT) and stages of hypertensive disease of pregnancy by comparing values in groups with healthy pregnancies, gestational hypertension [GHT], preeclampsia with proteinuria [PE + P] and severe preeclampsia with proteinuria [sPE + P]. The secondary aim was to investigate how proteinuria affects PCT values in these patients.

Materials And Methods: This was a retrospective cohort study.

View Article and Find Full Text PDF

Prompt diagnosis of preeclampsia is key to ensure appropriate management and reduce associated adverse outcomes. Placental growth factor (PlGF)-based biomarkers have been shown to be safe and effective diagnostic tools for preterm preeclampsia, and their use is recommended by most recent Canadian guidelines. The present report summarizes an expert panel discussion that led to the development of a proposed utilization algorithm for PlGF-based diagnostic testing for suspected preeclampsia in Québec.

View Article and Find Full Text PDF

Trends in Antepartum, Delivery, and Postpartum Venous Thromboembolism.

Obstet Gynecol

January 2025

Rutgers New Jersey Medical School, Newark, New Jersey; the Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York; and the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California.

Objective: To assess trends in risk for obstetric venous thromboembolism (VTE).

Methods: This retrospective cohort study analyzed data from the 2008-2019 Merative MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 15-54 years with a delivery hospitalization and health care enrollment from 1 year before pregnancy to 60 days after delivery were identified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!